Visit
Thanks for your feedback, this will help us improve our content for you!
Thank for your feedback, this will help us improve our content for you!
Prof Paul Richardson (Dana-Farber Cancer Institute, Boston, MA) summarises of results of clinical trials in the management of relapsed or refractory multiple myeloma presented at the 2014 American Society of Hematology (ASH) Annual Meeting.
Investigational agents discussed include: proteasome inhibitor, carfilzomib; anti-CD38 monoclonal antibody, daratumumab: anti-SLAMF7 monoclonal antibody, elotuzumab; histone deacetylase (HDAC) inhibitor, panobinostat; HDAC6 inhibitor, ricolinostat; immunomodulatory agent, pomalidomide.
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest hemonc news and updates
Keep up to date with all the latest news with our monthly newsletter